Article

Sue Friedman on Informed Decision-Making in Hereditary Breast and Ovarian Cancers

Author(s):

Sue Friedman

Sue Friedman, Executive Director, FORCE (Facing Our Risk of Cancer Empowered), discusses the ABOUT Network and the importance of informed decision-making.

Sue Friedman, Executive Director, FORCE (Facing Our Risk of Cancer Empowered), discusses the ABOUT Network, which is the first-ever patient-powered research registry created and governed by and for people affected by hereditary breast and ovarian cancers. In this clip, Friedman also stresses the importance of informed decision-making.

Related Videos
Image of Dr. Braun.
Dr. Sattva S. Neelapu is a professor and deputy department chair in the Department of Lymphoma/Myeloma, Division of Cancer Medicine, at The University of Texas MD Anderson Cancer Center, in Houston, as well as a member of Graduate Faculty, Immunology Program, Graduate School of Biomedical Sciences, at The University of Texas Health Science Center, also located in Houston.
Dr. Azka Ali is a medical oncologist at the Cleveland Clinic Taussig Cancer Institute, in Ohio.
Dr. Maxwell Lloyd, a Clinical Fellow in Medicine in the Department of Medicine at Beth Israel Deaconess Medical Center in Boston.
Dr. Michael Bogenschutz
Photo credit: Max Mumby/Indigo via Getty Images
Dr. Maxwell Lloyd, a Clinical Fellow in Medicine, in the Department of Medicine, at Beth Israel Deaconess Medical Center in Boston.
Dr. Stephanie Alice Baker
Dr. Aditya Bardia is a professor in the Department of Medicine, Division of Hematology/Oncology, director of Translational Research Integration, and a member Signal Transduction and Therapeutics, at University of California, Los Angeles (UCLA) Health Jonsson Comprehensive Cancer Center.
Related Content
Image of blood-based test.
January 22nd 2025

Understanding the Concept of MRD for Patients With Cancer

Ryan Scott
Dr. Christopher Flowers discusses MRD testing in cancer care, why this is an important concept to understand and how it relates to recurrence in patients.
cancer horizons logo: a white microphone on a navy blue background
March 11th 2024

Oncology Approvals, Psychological Outcomes for Survivors and an Ovarian Cancer Vaccine

Alex Biese Brielle Benyon
Last week we saw some FDA approvals come through, as well as research that explored the psychosocial outcomes of individuals who survived pediatric rhabdosarcoma.
Credit: Paul Archuleta - Getty Images
January 17th 2025

‘Nanny 911’ Star Deborah Finck Died, Danielle Fishel Completed Radiation and More

Alex Biese
From the death of a TikTok influencer to an update from a “Boy Meets World” star, here is this week’s news.
FDA, Cancer Vaccine Updates and a Misguiding of Breast Cancer Treatment
February 5th 2024

FDA, Cancer Vaccine Updates and a Misguiding of Breast Cancer Treatment

Alex Biese Brielle Benyon
One cancer vaccine may still be years away from being available, a breast cancer test may be misguiding treatments for Black women and the review of two oncology regimens are being expedited by the FDA.
Image of pills that spell "side FX"
January 15th 2025

Elinzanetant May Treat Hot Flashes Caused by Breast Cancer Treatment

Spencer Feldman
Elinzanetant significantly reduced the frequency and severity of hot flashes in women with breast cancer who were undergoing hormone therapy.
Illustration of female reproductive system.
January 13th 2025

HIPEC May Not Improve Outcomes for Recurrent Epithelial Ovarian Cancer

Spencer Feldman
Adding hyperthermic intraperitoneal chemotherapy to surgery did not improve progression-free survival in platinum-sensitive recurrent ovarian cancer.